France Covid Vaccine Packaging Market Size & Outlook, 2026-2034
France Covid Vaccine Packaging Market Insights
- As per Packaging Market Insights, the France Covid Vaccine Packaging Market stood at USD 124.07 Million in 2025 and is anticipated to grow to USD 200.08 Million by 2034.
- The France market is expected to advance at a CAGR of 5.44% from 2026 through 2034.
- In 2025, Glass Vials accounted for the highest share of the Product Type market size.
- During the forecast period, Prefilled Syringes is set to register the highest growth, making it the most lucrative Product Type segment.
Source: PIAnalysis Company Publications, Primary Interviews.
Other Key Findings
- France contributed 4.56% to the global Covid Vaccine Packaging Market size in 2025.
- By 2034, United States is forecasted to remain the largest global market for Covid Vaccine Packaging Market.
- In Europe, Germany is projected to capture the leading share of market size by 2034.
- Among Europe markets, Germany is expected to post the fastest growth, reaching USD 343.1 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 124.07 Million |
| Market Size In 2034 | USD 200.08 Million |
| Largest segment | Glass Vials |
| Units | Revenue in USD Million |
| CAGR | 5.44% (2026-2034) |
| Segmnetation Covered | |
| Product Type |
|
| Application |
|
| Distribution Channel |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
France Covid Vaccine Packaging Market Product Type 2026-2034 (USD Million)
| Product Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glass Vials | XX.x | XX.x | XX.x | 66.64 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Prefilled Syringes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Secondary Packaging | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.
France Covid Vaccine Packaging Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mRNA Vaccines | XX.x | XX.x | XX.x | 60.78 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Viral Vector Vaccines | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Protein Subunit Vaccines | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.
France Covid Vaccine Packaging Market Distribution Channel 2026-2034 (USD Million)
| Distribution Channel | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Direct Supply to Pharmaceutical Companies | XX.x | XX.x | XX.x | 43.42 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Medical & Pharmaceutical Distributors | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Government Procurement | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hospital & Healthcare Networks | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Contract Packaging Organizations | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.